| 0 (0%) | 10-15 12:15 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.07 | 1-year : | 4.76 |
| Resists | First : | 3.49 | Second : | 4.07 |
| Pivot price | 2.62 |
|||
| Supports | First : | 2.38 | Second : | 1.7 |
| MAs | MA(5) : | 3.13 |
MA(20) : | 2.49 |
| MA(100) : | 2.11 |
MA(250) : | 1.65 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 90.1  |
D(3) : | 92.3 |
| RSI | RSI(14): 77.1 |
|||
| 52-week | High : | 3.49 | Low : | 0.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ APYX ] has closed below upper band by 12.6%. Bollinger Bands are 201.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.49 - 3.51 | 3.51 - 3.52 |
| Low: | 2.84 - 2.85 | 2.85 - 2.87 |
| Close: | 3.38 - 3.4 | 3.4 - 3.42 |
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Wed, 15 Oct 2025
Hold Rating for Apyx Medical Amid Promising Ayon System and Challenging Market Conditions - TipRanks
Wed, 15 Oct 2025
Apyx Medical stock rating reiterated by Citizens on AYON system rollout - Investing.com UK
Wed, 15 Oct 2025
Using data filters to optimize entry into Apyx Medical Corporation - July 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
Wed, 15 Oct 2025
Published on: 2025-10-15 03:28:43 - newser.com
Mon, 13 Oct 2025
Apyx Medical submits FDA 510k to U.S. FDA for label expansion of AYON - TipRanks
Mon, 13 Oct 2025
510(k) Submission Seeks FDA Label Expansion to Add AYON Power Liposuction; Nationwide launch began Sept 2025 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 38 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 14.5 (%) |
| Held by Institutions | 42.2 (%) |
| Shares Short | 260 (K) |
| Shares Short P.Month | 232 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | -37.2 % |
| Operating Margin | -22.7 % |
| Return on Assets (ttm) | -12.5 % |
| Return on Equity (ttm) | -154.6 % |
| Qtrly Rev. Growth | -6.5 % |
| Gross Profit (p.s.) | 0.75 |
| Sales Per Share | 1.22 |
| EBITDA (p.s.) | -0.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -7.57 |
| PEG Ratio | 0 |
| Price to Book value | 17.52 |
| Price to Sales | 2.7 |
| Price to Cash Flow | -13.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|